SCHEMBL5585975

SCHEMBL5585975

CNCC(=O)Nc1cc(Cn2ccc3c(NC(=O)Nc4cc(Br)ccc4OC)cccc32)ccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.43
EPHB4 P54760 1/20 0.43
TEK Q02763 1/20 0.43
IRAK4 Q9NWZ3 1/20 0.40
MAPT P10636 3/20 0.38
USP2 O75604 1/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
KDM4E B2RXH2 2/20 0.38
THRB P10828 2/20 0.37
THRA P10827 1/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ERBB4 Q15303 3/20 0.37
HCK P08631 3/20 0.36
MAPK12 P53778 3/20 0.36
MAPK14 Q16539 3/20 0.36
SRC P12931 1/20 0.36
EGFR P00533 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5586061 0.92 ERBB4 (0.44) KDREPHB4TEKIRAK4MAPT
SCHEMBL5586127 0.92 KDR (0.43) KDREPHB4TEKIRAK4MAPT
SCHEMBL5592592 0.92 KDR (0.45) KDREPHB4TEKIRAK4MAPT
SCHEMBL5586002 0.92 KDR (0.43) KDREPHB4TEKIRAK4MAPT
SCHEMBL5592851 0.91 EPHB4 (0.45) KDREPHB4TEKIRAK4MAPT
SCHEMBL5600303 0.91 MEN1 (0.45) EPHB4MAPTKDM4ETHRBMEN1
SCHEMBL5586052 0.91 KDR (0.44) KDREPHB4TEKIRAK4MAPT
SCHEMBL5585926 0.91 KDR (0.44) KDREPHB4TEKIRAK4MAPT
SCHEMBL5586136 0.90 HCK (0.43) KDREPHB4TEKIRAK4MAPT
SCHEMBL5592635 0.89 KDR (0.43) KDREPHB4TEKIRAK4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP claimed
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity GILEAD CONNECTICUT, INC. 2006-09-07 US claimed
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP disclosed
EP-2397478-A1 1,3-diaryl substituted ureas as modulators of kinase activity. CGI Pharmaceuticals, Inc. (US) 2011-12-21 EP disclosed
EP-1858879-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI Pharmaceuticals, Inc. (US) 2007-11-28 EP disclosed
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity GILEAD CONNECTICUT, INC. 2006-09-07 US disclosed
WO-2006076593-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI PHARMACEUTICALS, INC. (US) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity UCK2, CHUK, AXL KDR 72/4885EPHB4 3357/4885TEK 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.